Oric Pharmaceuticals Net Worth
Oric Pharmaceuticals Net Worth Breakdown | ORIC |
Oric Pharmaceuticals Net Worth Analysis
Oric Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Oric Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Oric Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Oric Pharmaceuticals' net worth analysis. One common approach is to calculate Oric Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Oric Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Oric Pharmaceuticals' net worth. This approach calculates the present value of Oric Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Oric Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Oric Pharmaceuticals' net worth. This involves comparing Oric Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Oric Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Oric Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Oric Pharmaceuticals' net worth research are outlined below:
| Oric Pharmaceuticals generated a negative expected return over the last 90 days | |
| Oric Pharmaceuticals has high historical volatility and very poor performance | |
| Net Loss for the year was (100.7 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Oric Pharmaceuticals currently holds about 227.06 M in cash with (85.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.74. | |
| Oric Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Over 91.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: ORIC Working with Two Pharma Giants, Analysts See 100 percent Upside - MSN |
Oric Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Oric Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Oric Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Oric Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Oric Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Oric Pharmaceuticals backward and forwards among themselves. Oric Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Oric Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Boxer Capital Llc | 2024-09-30 | 1.7 M | Nea Management Company, Llc | 2024-06-30 | 1.5 M | First Turn Management Llc | 2024-09-30 | 1.5 M | Vivo Capital, Llc | 2024-09-30 | 1.3 M | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-06-30 | 1.3 M | Geode Capital Management, Llc | 2024-06-30 | 1.2 M | T. Rowe Price Associates, Inc. | 2024-06-30 | 1.2 M | Silverarc Capital Management, Llc | 2024-06-30 | 1.1 M | Invus Financial Advisors, Llc | 2024-06-30 | 1 M | Nextech Invest Ag | 2024-09-30 | 5.3 M | Blackrock Inc | 2024-06-30 | 4.8 M |
Follow Oric Pharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 676.74 M.Market Cap |
|
Project Oric Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.40) | (0.42) | |
| Return On Capital Employed | (0.48) | (0.50) | |
| Return On Assets | (0.40) | (0.42) | |
| Return On Equity | (0.45) | (0.47) |
When accessing Oric Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Oric Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Oric Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the presentation of Oric Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Oric Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Oric Pharmaceuticals' management manipulating its earnings.
Evaluate Oric Pharmaceuticals' management efficiency
Oric Pharmaceuticals has return on total asset (ROA) of (0.2922) % which means that it has lost $0.2922 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4598) %, meaning that it created substantial loss on money invested by shareholders. Oric Pharmaceuticals' management efficiency ratios could be used to measure how well Oric Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of November 23, 2024, Return On Tangible Assets is expected to decline to -0.42. In addition to that, Return On Capital Employed is expected to decline to -0.5. The current year's Net Tangible Assets is expected to grow to about 268.5 M, whereas Other Assets are forecasted to decline to about 433.8 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.36 | 3.52 | |
| Tangible Book Value Per Share | 4.36 | 3.54 | |
| Enterprise Value Over EBITDA | (4.19) | (4.40) | |
| Price Book Value Ratio | 2.11 | 2.01 | |
| Enterprise Value Multiple | (4.19) | (4.40) | |
| Price Fair Value | 2.11 | 2.01 | |
| Enterprise Value | 460.2 M | 581.3 M |
The operational strategies employed by Oric Pharmaceuticals management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Return On Equity (0.46) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Oric Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Oric Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Oric Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Oric Pharmaceuticals Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 12th of August 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 4th of June 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Oric Pharmaceuticals Earnings per Share Projection vs Actual
Oric Pharmaceuticals Corporate Management
| CPA CPA | Chief Officer | Profile | |
| BA BA | CoFounder Board | Profile | |
| Lori Friedman | Chief Officer | Profile | |
| Esq JD | G Counsel | Profile | |
| MS MD | Chief Officer | Profile | |
| Richard Heyman | Independent CoFounder | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oric Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For information on how to trade Oric Stock refer to our How to Trade Oric Stock guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oric Pharmaceuticals. If investors know Oric will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oric Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.82) | Return On Assets (0.29) | Return On Equity (0.46) |
The market value of Oric Pharmaceuticals is measured differently than its book value, which is the value of Oric that is recorded on the company's balance sheet. Investors also form their own opinion of Oric Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Oric Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oric Pharmaceuticals' market value can be influenced by many factors that don't directly affect Oric Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oric Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oric Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oric Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.